Therini Bio CEO Mike Quigley (L) and Katerina Akassoglou

Ex­clu­sive: Theri­ni rais­es $36M, will tar­get fib­rin pro­tein for Alzheimer's and di­a­bet­ic mac­u­lar ede­ma

Theri­ni Bio has raised a $36 mil­lion Se­ries A and will head to the clin­ic with an an­ti­body that neu­tral­izes fib­rin, a blood clot­ting pro­tein …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.